Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
0 hedge funds and large institutions have $0 invested in Genomic Health, Inc. in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 219 closing their positions.
100% less funds holding
Funds holding: 221 → 0 (-221)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $2.44B → $0 (-$2.44B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 219
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$627M |
| 2 |
BlackRock
New York
|
-$276M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$187M |
| 4 |
Renaissance Technologies
New York
|
-$170M |
| 5 |
State Street
Boston,
Massachusetts
|
-$98.2M |
GHDX Hedge Fund Activity: Q4 2019 in Review
0 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q4 2019, worth a combined $0 — down 100% from $2.44B a quarter earlier.
Sellers outnumbered buyers: 219 funds closed out of GHDX and 0 opened new positions — a net loss of 219 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $627M sold.
- 0 institutional investors held Genomic Health, Inc. (GHDX) as of Q4 2019, down from 221 in Q3 2019.
- Funds reported $0 of Genomic Health, Inc. stock for Q4 2019, down 100% quarter-over-quarter.
- 0 funds opened new Genomic Health, Inc. positions in Q4 2019 and 219 closed out, a net change of -219 holders.
- The largest Genomic Health, Inc. seller in Q4 2019 was Baker Bros. Advisors, an estimated $627M sold.
Based on aggregated 13F filings for Q4 2019.